Bicycle Therapeutics plc (NASDAQ:BCYC) Receives Average Recommendation of “Moderate Buy” from Analysts

Bicycle Therapeutics plc (NASDAQ:BCYC) has received a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $46.86.

Several analysts have commented on the stock. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of Bicycle Therapeutics in a report on Friday, May 3rd. Needham & Company LLC restated a “buy” rating and set a $43.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, April 10th.

Insider Activity

In other news, CEO Kevin Lee sold 3,158 shares of Bicycle Therapeutics stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $23.81, for a total value of $75,191.98. Following the sale, the chief executive officer now directly owns 387,270 shares in the company, valued at $9,220,898.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 5,312 shares of company stock worth $126,139 over the last ninety days. Insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Baker BROS. Advisors LP grew its stake in shares of Bicycle Therapeutics by 176.1% in the first quarter. Baker BROS. Advisors LP now owns 4,942,823 shares of the company’s stock valued at $123,076,000 after buying an additional 3,152,433 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Bicycle Therapeutics by 45.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 401,646 shares of the company’s stock valued at $10,001,000 after buying an additional 124,809 shares in the last quarter. Westfield Capital Management Co. LP grew its stake in shares of Bicycle Therapeutics by 13.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,038,917 shares of the company’s stock valued at $25,869,000 after buying an additional 121,613 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Bicycle Therapeutics by 12.8% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 883,105 shares of the company’s stock valued at $21,989,000 after buying an additional 100,107 shares in the last quarter. Finally, Concurrent Investment Advisors LLC bought a new position in shares of Bicycle Therapeutics in the first quarter valued at $543,000. 86.15% of the stock is owned by institutional investors.

Bicycle Therapeutics Stock Performance

Shares of BCYC stock opened at $20.53 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.42 and a current ratio of 10.42. The company has a market capitalization of $878.27 million, a P/E ratio of -4.61 and a beta of 0.88. The company’s 50 day moving average price is $22.71 and its two-hundred day moving average price is $21.42. Bicycle Therapeutics has a 52 week low of $12.54 and a 52 week high of $27.96.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Thursday, May 2nd. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($1.25) by $0.63. The firm had revenue of $19.53 million for the quarter, compared to the consensus estimate of $6.06 million. Bicycle Therapeutics had a negative net margin of 404.14% and a negative return on equity of 49.35%. Bicycle Therapeutics’s revenue for the quarter was up 298.9% compared to the same quarter last year. On average, analysts expect that Bicycle Therapeutics will post -4.44 earnings per share for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.